SeaCrest Wealth Management’s Emergent Biosolutions EBS Stock Holding History

SeaCrest Wealth Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-106,700	Closed	-$519K	–	637
2025 Q1	$519K	Buy	106,700 +13,000	+14%	+$108K	0.06%	323
2024 Q4	$896K	Sell	93,700 -25,000	-21%	-$229K	0.09%	202
2024 Q3	$991K	Buy	118,700 +3,705	+3%	+$33.7K	0.11%	190
2024 Q2	$784K	Buy	114,995 +18,995	+20%	+$81.7K	0.09%	216
2024 Q1	$243K	Buy	+96,000	New	+$216K	0.03%	510
2019 Q2	–	Sell	-79	Closed	-$4K	–	865
2019 Q1	$4K	Hold	79	–	–	﹤0.01%	1767
2018 Q4	$5K	Hold	79	–	–	﹤0.01%	1685
2018 Q3	$5K	Sell	79 -30	-28%	-$1.75K	﹤0.01%	1850
2018 Q2	$6K	Hold	109	–	–	﹤0.01%	1758
2018 Q1	$6K	Hold	109	–	–	﹤0.01%	1731
2017 Q4	$5K	Buy	+109	New	+$4.59K	﹤0.01%	1792

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SeaCrest Wealth Management's EBS Position: Q2 2025 in Review

SeaCrest Wealth Management sold out of Emergent Biosolutions (EBS) in Q2 2025, closing a stake of 106,700 shares — an estimated $519K sold.

SeaCrest Wealth Management first reported a position in EBS in Q4 2017 and held it in 11 quarters. The position peaked at $991K in Q3 2024. 161 funds tracked by Wall St. Rank hold EBS as of Q2 2025.

SeaCrest Wealth Management reported no remaining Emergent Biosolutions position as of Q2 2025 after selling out during the quarter.
SeaCrest Wealth Management sold 106,700 Emergent Biosolutions shares in Q2 2025, an estimated $519K.
SeaCrest Wealth Management first reported a position in Emergent Biosolutions in Q4 2017 and held it in 11 quarters.
SeaCrest Wealth Management's Emergent Biosolutions position peaked at $991K in Q3 2024.
161 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2025.

Based on SeaCrest Wealth Management's 13F filing for Q2 2025, filed 11 Jul 2025.